Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GSK names Johns Hopkins scientist to board ahead of consumer unit spinoff

10/27/2021 | 04:04am EST
FILE PHOTO: A GlaxoSmithKline plant is seen in Montrose, Scotland, Britain

(Reuters) - GlaxoSmithKline on Wednesday named a genetics professor to its board, as it refocuses on its pharmaceuticals business following a planned separation of the consumer healthcare division next year, while looking to appease investors.

The London-listed British conglomerate said Harry Dietz, who teaches genetic medicine at Johns Hopkins University in the United States, would join GSK as a non-executive director, beginning Jan. 2022.

"Continuing to strengthen our R&D pipeline remains a key long-term priority as we prepare for the demerger," said GSK Chairman Jonathan Symonds, adding that Dietz's expertise would provide the company with the insight it would need.

Activist investors Elliott and Bluebell have called for changes at GSK, including an outright sale of its consumer unit, which is a joint venture with Pfizer Inc, along with a leadership and board shakeup at "New GSK".

GSK in July rejected Elliott's demands, noting the board appointments it had already made. This month, it also contended claims from Bluebell, adding that it was "firmly on track" for the separation in 2022 as planned.

Dietz will join GSK's Science Committee and his appointment follows that of former Bristol-Myers Squibb executive Charles Bancroft and Anne Beal, an entrepreneur, health policy expert and paediatrician, to the board in May 2020 and May 2021 respectively.

GSK set out plans in June to turn the consumer arm, which makes Sensodyne toothpaste, and Advil and Panadol painkillers, into a separately listed firm and focus on its underperforming drugs business.

The company is slated to report third-quarter results later in the day.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Anil D'Silva)


© Reuters 2021
All news about GLAXOSMITHKLINE PLC
11/28GlaxoSmithKline Set to Begin Human Trials for HIV Treatment in 2022
MT
11/24BiondVax Pharmaceuticals Schedules Shareholder Meeting Amid Preparations to Produce VHH..
MT
11/24GLAXOSMITHKLINE : UBS reiterates its Neutral rating
MD
11/23GLOBAL MARKETS LIVE : Samsung, Clariant, AstraZeneca, Amazon, Merck...
11/23Health Care Stocks Flat Ahead of Tuesday's Opening Bell
MT
11/23GLAXOSMITHKLINE : Gets a Buy rating from Berenberg
MD
11/22GlaxoSmithKline Secures Exclusive License Deal for Arrowhead's Liver Disease Treatment
MT
11/22Arrowhead Pharmaceuticals Reports Wider Fiscal 2021 Loss, Signs License Deal With GSK f..
MT
11/22Arrowhead Pharma in License Agreement With GSK for ARO-HSD
DJ
11/22GLAXOSMITHKLINE : UBS remains Neutral
MD
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Financials
Sales 2021 33 843 M 45 122 M 45 122 M
Net income 2021 4 027 M 5 370 M 5 370 M
Net Debt 2021 20 703 M 27 603 M 27 603 M
P/E ratio 2021 18,7x
Yield 2021 5,30%
Capitalization 75 660 M 101 B 101 B
EV / Sales 2021 2,85x
EV / Sales 2022 2,69x
Nbr of Employees 94 066
Free-Float 92,3%
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | MarketScreener
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 1 510,80 GBX
Average target price 1 675,24 GBX
Spread / Average Target 10,9%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GLAXOSMITHKLINE PLC12.58%100 759
JOHNSON & JOHNSON1.82%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049